Mainz Biomed NV

Insider buying surge at Mainz Biomed NV signals confidence in pancreatic‑cancer diagnostics and new capital raise—could spark a stock rally.

Insider buying surges at Mainz Biomed, signaling confidence despite flat price—could it spark a rebound in a biotech on the brink of clinical milestones?

Watch Mainz Biomed NV insider moves: early stock‑option vesting and executive trades may signal a looming dilution or a strategic turnaround in diagnostic tech.